Strs Ohio Raises Stock Position in Inari Medical, Inc. (NASDAQ:NARI)

Strs Ohio grew its holdings in Inari Medical, Inc. (NASDAQ:NARI) by 27.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,100 shares of the company’s stock after buying an additional 1,300 shares during the period. Strs Ohio’s holdings in Inari Medical were worth $396,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Fifth Third Bancorp grew its stake in shares of Inari Medical by 54.3% in the 3rd quarter. Fifth Third Bancorp now owns 486 shares of the company’s stock worth $32,000 after buying an additional 171 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Inari Medical by 139.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,189 shares of the company’s stock worth $78,000 after acquiring an additional 693 shares during the last quarter. Handelsinvest Investeringsforvaltning bought a new stake in shares of Inari Medical in the 4th quarter worth about $185,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Inari Medical in the 3rd quarter worth about $204,000. Finally, Blair William & Co. IL bought a new stake in shares of Inari Medical in the 3rd quarter worth about $205,000. 90.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NARI has been the subject of a number of research analyst reports. Piper Sandler lowered shares of Inari Medical from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $85.00 to $55.00 in a report on Thursday, February 29th. Truist Financial decreased their price objective on shares of Inari Medical from $61.00 to $52.00 and set a “hold” rating for the company in a report on Friday, March 22nd. Canaccord Genuity Group reiterated a “buy” rating and set a $75.00 price objective on shares of Inari Medical in a report on Friday, April 12th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $72.00 price objective on shares of Inari Medical in a report on Wednesday, March 6th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Inari Medical currently has an average rating of “Moderate Buy” and an average price target of $73.71.

Insider Transactions at Inari Medical

In other news, CFO Mitch C. Hill sold 6,000 shares of Inari Medical stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $40.96, for a total value of $245,760.00. Following the transaction, the chief financial officer now owns 181,294 shares of the company’s stock, valued at approximately $7,425,802.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CFO Mitch C. Hill sold 6,000 shares of Inari Medical stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $40.96, for a total value of $245,760.00. Following the transaction, the chief financial officer now owns 181,294 shares of the company’s stock, valued at approximately $7,425,802.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director William Hoffman sold 1,451 shares of Inari Medical stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $40.00, for a total transaction of $58,040.00. Following the completion of the transaction, the director now directly owns 999,782 shares in the company, valued at approximately $39,991,280. The disclosure for this sale can be found here. Insiders have sold a total of 47,451 shares of company stock valued at $1,949,000 in the last 90 days. Insiders own 10.60% of the company’s stock.

Inari Medical Stock Performance

NASDAQ:NARI opened at $38.42 on Monday. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $71.85. The firm has a market cap of $2.23 billion, a P/E ratio of -1,280.67 and a beta of 0.84. The firm has a 50-day simple moving average of $44.86 and a 200-day simple moving average of $54.24.

Inari Medical (NASDAQ:NARI) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.09). Inari Medical had a negative net margin of 0.33% and a positive return on equity of 1.23%. The business had revenue of $132.10 million during the quarter, compared to the consensus estimate of $131.82 million. During the same quarter in the prior year, the firm posted ($0.11) EPS. The company’s revenue for the quarter was up 22.5% compared to the same quarter last year. On average, research analysts predict that Inari Medical, Inc. will post -0.25 EPS for the current fiscal year.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.